At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 232 enrolled
Drug / intervention
AGN-195263 0.1% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
In Brief
A Phase 2 clinical trial evaluating AGN-195263 0.1%, AGN-195263 0.03%, and 2 other interventions for Meibomian Gland Dysfunction. Completed, enrolled 232 participants across 33 sites.
Detailed Summary
This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartAug 2012
Primary CompletionFeb 2015
TodayJul 2026
First PostedJul 4, 2012
Enrollment StartAug 22, 2012
Primary CompletionFeb 5, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.0 years ago
Interventions
AGN-195263 0.1%drug
1 drop of AGN-195263 0.1% instilled in each eye twice daily.
AGN-195263 0.03%drug
1 drop of AGN-195263 0.03% instilled in each eye twice daily.
AGN-195263 0.01%drug
1 drop of AGN-195263 0.01% instilled in each eye twice daily.
AGN-195263 Vehicledrug
1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.